MALARIA VACCINE DEVELOPMENT

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$49,000.00
Award Year:
1990
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Agency Tracking Number:
13633
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Medimmune Inc
19 Firstfield Rd, Gaithersburg, MD, 20878
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
James F Young
(301) 590-2622
Business Contact:
() -
Research Institution:
n/a
Abstract
MALARIA IS ONE OF THE MOST WIDESPREAD INFECTIOUS DISEASES OF HUMANS AND THREATENS ALMOST HALF OF THE WORLD'S POPULATION. CURRENTLY, THERE ARE AN ESTIMATED 350+ MILLION ACUTE CASES WORLDWIDE EACH YEAR, AND APPROXIMATELY 1 TO 2 MILLION INFANTS AND YOUNG CHILDREN DIE IN AFRICA ALONE BECAUSE OF THE DISEASE. TRADITIONAL METHODS OF CONTROLLING MALARIA WITH INSECTICIDES AND DRUGS HAVE BEEN INADEQUATE. THUS, INCREASED ATTENTION HAS FOCUSED ON DEVELOPING A SAFE AND EFFECTIVE VACCINE AGAINST THE PARASITE. IN PHASE I OF THIS PROJECT, THE OBJECTIVE IS TO ASSESS THE RELATIVE PROTECTIVE EFFICACY OF IMMUNIZATION WITH VARIOUS SYNTHETIC PEPTIDES BASED ON SEQUENCES FROM THE MAJOR SURFACE PROTEIN OF MALARIA SPOROZOITES. A PLASMODIUM BERGHEI RODENT MALARIA MODEL WILL BE USED BECAUSENO RELIABLE ANIMAL MODEL IS AVAILABLE FOR THE HUMAN MALARIA PARASITES, P. FALCIPARUM AND P. VIVAX. DATA FROM THIS STUDYWILL BE USED TO ESTABLISH PRINCIPLES THAT CAN BE APPLIED TO THE DEVELOPMENT OF NOVEL VACCINE CANDIDATES FOR THE HUMANMALARIA PARASITES.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government